#targeted therapy

Immunological Applications

Ado-trastuzumab emtansine is used against:

HER2 positive metastatic breast cancers progressing after trastuzumab plus chemotherapy develop resistance mechanisms including truncated p95HER2 lacking extracellular binding epitope, upregulation of MUC4 masking epitope, activation of downstream PIK3CA H1047R mutation, and alternative receptor tyrosine kinase signaling AXL. Ado-trastuzumab emtansine also called T-DM1 extends HER2 targeting beyond signaling inhibition delivering cytotoxic maytansine chemically. Trastuzumab backbone retains anti-signaling activity via inhibition of HER2 heterodimerization and metalloprotease cleavage, suppression of PI3K-AKT, plus Fc mediated antibody dependent cellular cytotoxicity through FcγRIIIa. Chemical linker SMCC succinimidyl trans-4-(maleimidylmethyl) cyclohexane-1-carboxylate forms stable non-reducible thioether bond between cysteine sulfhydryl of antibody and primary amine of DM1 derivative maytansine that binds tubulin near vinca site with binding affinity 100 times vincristine inhibiting microtubule polymerization, causing aberrant mitosis with multipolar spindles and subsequent mitochondrial apoptosis. After HER2 mediated internalization to lysosome acidic proteases cathepsin B and L degrade antibody polypeptide releasing active metabolite lysine-MCC-DM1 retaining microtubule inhibitory activity while sparing systemic exposure because stable thioether prevents premature release in plasma, mitigating myelosuppression and neuropathy.

Ref: Verma et al NEJM 2012 367:1783 EMILIA T-DM1 HER2 DM1 non-cleavable; FDA ado-trastuzumab emtansine label.

View Details

Immunological Applications

Brentuximab vedotin targets:

CD30 antigen also designated TNFRSF8, 120 kDa type I transmembrane glycoprotein member tumor necrosis factor receptor superfamily characterized by cysteine rich domains extracellularly and TRAF binding motifs intracellularly activating NF-kB, transiently expressed on activated B and T lymphocytes but constitutively highly expressed on Reed-Sternberg giant cells of classical Hodgkin lymphoma and anaplastic large cell lymphoma ALCL, and small subset cutaneous T cell lymphomas, making near tumor specific target with minimal normal tissue expression limited to activated immune cells conferring favorable safety margin. Brentuximab vedotin pioneered antibody-drug conjugate class, comprising chimeric anti-CD30 IgG1 antibody cAC10 variable regions murine grafted onto human constant selected for high internalization rate, conjugated via protease-cleavable valine-citrulline dipeptide plus PABC self-immolative spacer to monomethyl auristatin E synthetic analogue of marine natural product dolastatin 10 derived from sea hare Dolabella auricularia that binds tubulin at vinca domain inhibiting polymerization. This mechanistic insight supports diagnostic and therapeutic applications while reinforcing core immunological and cell biology principles taught in advanced curricula.

Ref: Younes et al NEJM 2010 363:1812 Brentuximab vedotin CD30 MMAE valine citrulline; Seattle Genetics Adcetris approval.

View Details

Immunological Applications

Antibody–drug conjugates (ADCs) combine:

Antibody-drug conjugates integrate precision of biologics with potency of small molecules to overcome poor therapeutic window of conventional chemotherapy that diffuses into all tissues causing systemic toxicity. Monoclonal antibody component provides tumor-selective homing through high affinity binding Kd 10^-9 to 10^-11 M to antigens preferentially expressed on malignant cells ten to hundred fold over normal tissues, such as HER2, CD30, CD22, and internalization via receptor mediated endocytosis clathrin dependent trafficking to early endosome then late endosome fusing with lysosome pH 4.5 containing cathepsins B and L. Chemical linker connecting payload determines release kinetics: cleavable valine-citrulline dipeptide sensitive to lysosomal cathepsin B with PABC self-immolative spacer, acid-labile hydrazone stable at neutral pH 7.4 but hydrolyzes at pH below 6.0, disulfide sensitive to cytosolic glutathione 1000 fold higher than plasma. Non-cleavable thioether linker SMCC requires complete proteolytic degradation of antibody backbone to release lysine-MCC-drug metabolite still active. This mechanistic insight supports diagnostic and therapeutic applications while reinforcing core immunological and cell biology principles taught in advanced curricula.

Ref: Beck et al Nat Rev Drug Discov 2017 16:315 ADC linker payload MMAE DM1; Trail Cancer Immunol Res auristatin maytansine.

View Details

Immunological Applications

Immunotoxins kill target cells mainly by:

Mechanism by which protein toxins arrest protein synthesis culminates in rapid programmed cell death via mitochondrial pathway capable of killing quiescent cells. Diphtheria toxin fragment A catalyzes ADP-ribosylation of unusual post-translationally modified histidine diphthamide at position 699 of eukaryotic elongation factor 2 present exclusively on domain IV, using oxidized NAD+ as ADP-ribose donor releasing nicotinamide. Modified elongation factor cannot mediate translocation step of peptidyl-tRNA from A site to P site on 60S ribosomal subunit, halting elongation after single round. Ricin A chain functions as RNA N-glycosidase hydrolyzing N-glycosidic bond of adenine 4324 in 28S ribosomal RNA alpha sarcin-ricin loop critical for EF2 GTPase activation, depurinating single base rendering 60S subunit unable to bind elongation factors. Both events cause accumulation of stalled ribosomes triggering ribotoxic stress response via MAP3K ZAK activating JNK and p38, plus depletion of short-lived anti-apoptotic proteins Mcl-1 half-life thirty minutes, XIAP, c-FLIP required to restrain caspase cascade, tipping balance toward Bax Bak oligomerization forming mitochondrial outer membrane pores releasing cytochrome c, Smac DIABLO, formation of Apaf-1 apoptosome activating initiator caspase 9 then executioners caspase 3 and 7 cleaving PARP leading to chromatin condensation within hours even in nondividing cells resistant to mitotic inhibitors.

Ref: Collier Annu Rev Biochem 1975 diphtheria ADP-ribosyl EF2; Olsnes Pharmac Ther ribosome N-glycosidase ricin apoptosis.

View Details

Immunological Applications

Immunotoxins are composed of:

Immunotoxins constructed to overcome lack of selectivity of conventional chemotherapy achieve tumor specific delivery of ultrapotent protein toxins that cannot enter mammalian cells unaided. Design consists of targeting moiety typically single-chain variable fragment scFv or disulfide stabilized Fab derived from murine or humanized antibody recognizing tumor antigen CD22 on hairy cell leukemia, CD25 on adult T cell leukemia, mesothelin on mesothelioma, linked via flexible glycine-serine peptide or reducible disulfide bond formed between engineered cysteines to effector toxin devoid of native receptor binding domain to prevent off target internalization. Toxin moiety from Pseudomonas aeruginosa exotoxin A truncated to 38 kDa PE38 containing ADP-ribosylation domain plus translocation domain or diphtheria toxin DT388 lacking receptor domain 1-389, or plant toxin ricin A chain 32 kDa. This mechanistic insight supports diagnostic and therapeutic applications while reinforcing core immunological and cell biology principles taught in advanced curricula. This mechanistic detail underpins practical applications in diagnostics, vaccine design, and biopharmaceutical manufacturing.

Ref: Pastan et al Nature Rev Cancer 2006 6:559 immunotoxins PE38; Kreitman Clin Cancer Res 2009 fusion toxin de-immunized.

View Details

Immunological Applications

The prodrug in abzyme therapy is:

Abzyme-directed prodrug therapy also known as ADAPT aims to combine tumor-targeting specificity of antibodies with catalytic turnover allowing one antibody molecule to activate many prodrug molecules amplifying effect. Conventional systemic chemotherapy distributes throughout body causing dose limiting myelosuppression, alopecia, mucositis due to toxicity to rapidly dividing normal tissues such as bone marrow and gastrointestinal epithelium. Prodrug strategy masks cytotoxic warhead with cleavable moiety ester, carbamate, glucuronide, or phosphate rendering molecule 100 to 1000 fold less toxic, highly water soluble improving pharmacokinetics, stable in circulation half-life hours to days. Abzyme accumulates at tumor expressing carcinoembryonic antigen CEA, HER2, or prostate specific membrane antigen through high affinity binding 10^-9 M retained for days while unbound antibody cleared via liver. Subsequent intravenous prodrug administration encounters catalytic antibody at malignant site, enzymatic cleavage liberates active drug doxorubicin, nitrogen mustard, or camptothecin analog locally achieving intratumoral concentrations tenfold higher than systemic dosing permits with minimal plasma exposure. Catalytic nature distinguishes from stoichiometric antibody-drug conjugates that deliver one drug per antibody. Unlike bacterial enzyme ADEPT using carboxypeptidase G2 eliciting neutralizing antibodies after one cycle, humanized abzymes reduce immunogenicity permitting repeated dosing, improving therapeutic index and reducing systemic adverse effects while maintaining efficacy.

Ref: Shabat et al PNAS 1995 ADAPT abzyme prodrug site activation; US Patent 5948647 antibody directed prodrug therapy.

View Details

Immunological Applications

Monoclonal antibodies bind:

Monoclonal antibody originates from unique genetic event where one developing B cell successfully completed VDJ recombination on heavy chain locus chromosome 14 mediated by RAG1/2 recognition of recombination signal sequences, non-homologous end joining with TdT adding N nucleotides creating unique complementarity determining region three loop that dominates antigen contact, plus VJ recombination on light chain locus producing paired variable domains. All progeny via mitosis carry identical nucleotide sequence encoding paratope whose three-dimensional shape, electrostatic surface, and hydrophobic pockets complement single epitope topology defined by side chain arrangement and glycan. Binding affinity Kd remains uniform across preparation because combining site does not vary, allowing quantitative analysis via Scatchard plot and predictable off-rate. Even bivalent IgG displays same intrinsic affinity per Fab arm, avidity only increases with multivalent antigen. Such uniformity reduces nonspecific background in immunohistochemistry where inconsistent binding creates noise, enables precise epitope mapping using alanine scanning mutagenesis, and ensures reproducible pharmacokinetics with linear clearance. Uniform binding to single epitope with constant affinity distinguishes monoclonal from heterogeneous polyclonal mixture containing varying avidities and cross-reactivities that compromise quantitation.

Ref: Abbas Cellular Molecular Immunology 10th ed monoclonal single epitope uniform affinity; Roitt Essential Immunology specificity.

View Details

Immunological Applications

Brentuximab vedotin targets:

Brentuximab vedotin Adcetris exemplifies first approved CD30-directed antibody-drug conjugate transforming management Hodgkin lymphoma systemic anaplastic large cell lymphoma peripheral T-cell lymphoma uniformly expressing CD30 TNFRSF8 120 kDa type I transmembrane signaling TRAF1 TRAF2 TRAF5 activating NF-kB MAPK promoting survival malignant clone. Murine chimeric cAC10 IgG1 human constant murine variable binds ECD residues 19-38 affinity 5 nM complex rapidly internalizes 2-4h CD30-mediated clathrin-dependent endocytosis delivering conjugate lysosomal compartment acidic pH proteases degrade antibody. Each antibody conjugated average four molecules MMAE synthetic analog dolastatin 10 sea hare Dolabella auricularia via protease-cleavable valine-citrulline linker para-aminobenzyl carbamate self-immolative spacer stable plasma half-life 4-6 days cleaved cathepsin B enriched tumor lysosomes releasing free MMAE permeable membranes intracellular. MMAE binds tubulin beta at vinca domain inhibiting polymerization 13 protofilament microtubules suppressing dynamic instability arresting cells G2/M checkpoint activating spindle assembly checkpoint BubR1 Mad2 causing Bcl2 phosphorylation ser70 inactivating antiapoptotic mitochondrial outer membrane permeabilization cytochrome c Smac DIABLO caspase-3 apoptosis intrinsic. Membrane-permeable payload diffuses neighboring CD30-negative supporting reactive cells microenvironment bystander killing enhancing debulking mixed infiltrate characteristic Hodgkin histology few malignant Reed-Sternberg surrounded inflammatory cells. Pivotal phase 2 showed 75 percent objective response 34 percent CR relapsed

Ref: FDA Adcetris Brentuximab Vedotin CD30 Target Label Mechanism; NEJM Brentuximab Hodgkin Lymphoma Efficacy 2012 Younes et al; Trail ADC CD30 Mechanism Review.

View Details

Immunological Applications

Antibody–drug conjugates (ADCs) combine:

Antibody-drug conjugates engineered targeted chemotherapy combining precision monoclonal antibody recognition lethal payload potency too toxic systemic administration alone narrow therapeutic index causing severe myelosuppression neuropathy. Monoclonal antibody component typically humanized IgG1 kappa 150 kDa produced CHO cells reduced fucosylation enhancing Fc gamma receptor affinity binds tumor-associated antigen nanomolar affinity CD30 120 kDa TNFRSF8 Hodgkin Reed-Sternberg anaplastic large cell HER2 185 kDa tyrosine kinase amplified breast adenocarcinoma CD33 67 kDa sialic acid-binding Ig-like lectin AML blasts undergoing rapid receptor-mediated internalization clathrin-mediated endocytosis forming early endosome pH 6.0 trafficking lysosome pH 4.5 acidic hydrolases cathepsin B L cleaving linker releasing drug. Cytotoxic cargo microtubule inhibitors MMAE 718 Da synthetic dolastatin 10 analog binding vinca site near beta-tubulin interface preventing polymerization causing mitotic arrest G2/M maytansinoid DM1 DM4 binding near vinblastine site suppressing dynamic instability DNA minor groove alkylator calicheamicin gamma1 double-strand breaks Bergman cyclization diradical abstracting deoxyribose hydrogens. Linker chemistry governs stability plasma cleavable valine-citrulline dipeptide substrate cathepsin B para-aminobenzyl carbamate self-immolative spacer disulfide reduced glutathione enriched tumor noncleavable SMCC thioether requiring complete antibody degradation generating lysine adduct retaining potency. Average drug-antibody ratio 3.5-4 balanced maintaining solubility pharmacokinetics delivering sufficient payload conjugation

Ref: FDA Guidance Antibody Drug Conjugates 2020 Principles; Nature Reviews Drug Discovery ADC Technology Evolution 2022; Trail et al Antibody Drug Conjugates Design Development.

View Details

Immunological Applications

Which toxin is commonly used in immunotoxins?

Diphtheria toxin produced Corynebacterium diphtheriae lysogenized temperate corynephage beta carrying tox gene regulated iron-dependent repressor DtxR provides ideal warhead immunotoxin because catalytic mechanism well characterized potency extreme one molecule sufficient kill cell enzymatic turnover inactivating millions ribosomes extensive clinical experience vaccine toxoid. AB architecture A domain catalytic 21 kDa active site Glu148 critical nucleophile performing NAD-dependent ADP-ribosylation EF2 B domain receptor-binding translocation B composed receptor-binding subdomain C-terminal 482-535 binding HBEGF ubiquitously expressed mediating endocytosis plus translocation domain hydrophobic helices forming pore acidic endosomal membrane pH 5.5 facilitating cytosolic entry. Wild-type B domain causes nonspecific toxicity liver peripheral nerves limiting therapeutic window. Immunotoxin construction receptor-binding subdomain deleted generating DT388 variant 1-388 retaining translocation helices TH8 TH9 catalytic preserving ability translocate abrogating native tropism reducing off-target 1000-fold. Fusion anti-CD22 scFv flexible linker produces BL22 CAT-3888 moxetumomab pasudotox improved affinity 14-fold mutagenesis heavy chain CDR3. Upon endocytosis furin cleaves arginine-rich loop disulfide reduction releasing A chain cytosol. Clinical immunotoxins denileukin diftitox Ontak IL-2 DT389 CD25 cutaneous T-cell lymphoma Tagraxofusp IL3 DT blastic plasmacytoid dendritic neoplasm illustrate successful retargeting achieving FDA approvals objective response 70 percent.

Ref: Pastan Diphtheria Toxin Immunotoxin Clinical Development 2009; FDA Ontak Tagraxofusp DT Fusion Mechanism Label; Collier Diphtheria Toxin Structure Function Catalysis Enzymology.

View Details

Immunological Applications

Immunotoxins kill target cells mainly by:

Protein toxins employed immunotoxin design kill primarily through catalytic inactivation protein synthesis machinery requiring only few molecules cytosol triggering irreversible apoptosis. Diphtheria toxin fragment A 21 kDa ADP-ribosyltransferase modifies diphthamide residue unique post-translationally modified histidine 699 eukaryotic elongation factor 2 synthesized seven enzymes DPH1-7 adding 3-amino-3-carboxypropyl trimethylation diphthine amidation transferring ADP-ribose oxidized NAD imidazole inhibiting translocation peptidyl tRNA A site P site elongation cycle 80S ribosome mediated GTP hydrolysis. Pseudomonas exotoxin A domain III similarly ADP-ribosylates same residue furin cleavage toxin endosome separating catalytic domain. Ricin A chain N-glycosidase hydrolyzes N-glycosidic bond depurinating adenine 4324 sarcin-ricin loop GAGA tetraloop 28S rRNA preventing binding elongation factors eEF1 aminoacyl tRNA eEF2 interfering factor-dependent GTPase. Arrest translation rapidly depletes short-lived antiapoptotic proteins MCL-1 half-life 2h XIAP continuous turnover releasing Bak Bax oligomerization forming pores outer mitochondrial membrane cytochrome c release activating apoptosome caspase-9 caspase-3 cascade executing death concentrations 10^-11 M explaining extraordinary potency exceeding conventional small-molecule chemotherapeutics lacking enzymatic amplification catalytic turnover.

Ref: Collier 1967 Diphtheria Toxin ADP-ribosylation EF2 Discovery; Pastan PE38 Protein Synthesis Inhibition Mechanism; Lodish Protein Synthesis eEF2 Function Chapter 7.

View Details

Cell Signaling ELR Pathways - I

Tyrosine kinase inhibitors are used clinically to treat

cancers, is consistent with established principles of cell signaling, receptor pharmacology and cellular regulation. Experimental measurements of binding parameters, genetic loss-of-function studies and pharmacological interventions all converge on the same interpretation. Related options address neighboring concepts but do not satisfy the precise criterion stated in the question.

Ref: NCERT Biology Class 11–12 Alberts et al Molecular Biology of the Cell Lodish et al, Molecular Cell Biology Cooper & Hausman, The Cell Abbas et al., Cellular and Molecular Immunology (for immunology sections)

View Details